EUCTR2006-000715-19-FR
Active, not recruiting
Phase 1
A Long-Term Safety and Immunogenicity Follow-up of Healthy Adults Vaccinated with One Dose of Smallpox Vaccine (LISTER Strain).
Sanofi Pasteur SA0 sites230 target enrollmentMarch 29, 2006
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Five year follow-up of healthy adults already vaccinated in a previous trial
- Sponsor
- Sanofi Pasteur SA
- Enrollment
- 230
- Status
- Active, not recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Subject vaccinated and who completed the Phase II VVL04 trial.
- •2\) Informed consent form signed.
- •3\) Subject able to attend all scheduled visits and to comply with all trial procedures.
- •4\) Subject entitled to national social security.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •1\) Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Long-Term, Post treatment, Safety Follow-up, Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the GALLANT, GALLEX or ARMOR Studies, G-PLUS (GALLANT, GALLEX and ARMOR - Post treatment Long-term follow-Up Study) - G-PLUSType II Diabetes MellitusMedDRA version: 7Level: LLTClassification code 10045242EUCTR2005-001373-97-LTAstraZeneca AB4,500
Active, not recruiting
Not Applicable
A Long-Term, Post treatment, Safety Follow-up, Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the GALLANT, GALLEX or ARMOR Studies, G-PLUS (GALLANT, GALLEX and ARMOR - Post treatment Long-term follow-Up Study) - G-PLUSType II Diabetes MellitusMedDRA version: 7Level: LLTClassification code 10045242EUCTR2005-001373-97-FIAstraZeneca AB4,500
Active, not recruiting
Phase 1
A Long-Term, Post treatment, Safety Follow-up, Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the GALLANT, GALLEX or ARMOR Studies, G-PLUS (GALLANT, GALLEX and ARMOR - Post treatment Long-term follow-Up Study) - G-PLUSEUCTR2005-001373-97-GBAstraZeneca AB4,500
Active, not recruiting
Not Applicable
A Long-Term, Post treatment, Safety Follow-up, Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the GALLANT, GALLEX or ARMOR Studies, G-PLUS (GALLANT, GALLEX and ARMOR - Post treatment Long-term follow-Up Study) - G-PLUSType II Diabetes MellitusMedDRA version: 7Level: LLTClassification code 10045242EUCTR2005-001373-97-LVAstraZeneca AB4,500
Active, not recruiting
Not Applicable
A Long-Term, Post treatment, Safety Follow-up, Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the GALLANT, GALLEX or ARMOR Studies, G-PLUS (GALLANT, GALLEX and ARMOR - Post treatment Long-term follow-Up Study) - G-PLUSEUCTR2005-001373-97-EEAstraZeneca AB4,500